Precision Medicine Approaches for Neoadjuvant Therapy in High-risk Sarcoma Patients

ConditionsSarcoma Sarcoma, Leiomyo-, Adult Sarcoma, Synovial, Adult Soft Tissue Sarcoma (STS)Soft Tissue Sarcoma Adult Soft Tissue Sarcoma of the Trunk and Extremities Soft Tissue Sarcoma of the Limb Retroperitoneal Sarcoma Liposarcoma, Dedifferentiated Liposarcoma Leiomyosarcoma (LMS)Angiosarcoma

Trial statusRecruiting

Trial phaseNot listed

Trial typeObservational

Biological sexAll

Age18+

SponsorRoyal Marsden NHS Foundation Trust

About this trial

This is a cohort study aimed at developing a stratified medicine approach for personalised neoadjuvant chemotherapy (NCT) in high-risk soft tissue sarcoma (STS) patients with dedifferentiated liposarcoma (DDLPS), leiomyosarcoma (LMS), synovial sarcoma (SS), vascular sarcomas, malignant peripheral nerve sheath tumour (MPNST) or other subtypes. It comprises of both retrospective and prospective tissue collection from patients advancing directly to surgery (control group) and patients receiving NCT and surgery.

Eligibility criteria

Qualifiers

Written informed consent for the prospective cohort

Histopathological diagnosis of high-risk soft tissue sarcoma and one of the following subtypes: DDLPS, LMS, SS, vascular sarcomas or MPNST. Other subtypes may be included with PI approval.

Greater than 5cm or Grade 3

Deep anatomic location

Disqualifiers

Known additional malignancy that is progressing or requires active treatment

Metastatic disease not amenable to curative intent local therapy

Any active uncontrolled medical conditions

Trial design

Treatments tested in this trial

Observational Translational Study

Treatment groups

800 Participants

are divided into 2 treatment groups

Locations

The Royal Marsden HospitalSW3 6JJ, London United Kingdom

Sponsors and collaborators

Royal Marsden NHS Foundation Trust

Lead sponsor

Institute of Cancer Research, United Kingdom

Collaborator

University of Edinburgh

Collaborator

NHS Greater Glasgow and Clyde

Collaborator

University of Birmingham

Collaborator

University Hospital Birmingham

Collaborator

Cancer Research UK

Collaborator

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

Collaborator

Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz

Collaborator

Hospitales Universitarios Virgen del Rocío

Collaborator

Andalusian Network for Design and Translation of Advanced Therapies

Collaborator

Instituto de Biomedicina de Sevilla

Collaborator

the Fundación Científica de la Asociación Española Contra el Cáncer

Collaborator

Associazione Italiana per la Ricerca sul Cancro

Collaborator

Freeman Hospital, UK

Collaborator

Liverpool Hospital

Collaborator

The Clatterbridge Cancer Centre NHS Foundation Trust

Collaborator

Source ClinicalTrials.gov